(8)On 29 November 2019, the Authority requested additional information on the endocrine disrupting properties of pyraclostrobin pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012. The applicant submitted the information required to determine whether pyraclostrobin fulfils the criteria for identifying the endocrine disrupting properties of a substance set out in point 3.6.5 and point 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as introduced by Commission Regulation (EU) 2018/605note.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.